Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia

Next Previous
X
Search
Trial Profile

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Niacin (Primary)
  • Indications Hyperlipidaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type IIb
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Organon

    • Most Recent Events

    • 09 Sep 2009 Planned number of patients changed from 990 to 1220 as reported by ClinicalTrials.gov.
    • 14 Jun 2009 Results were presented at the 15th International Symposium on Atherosclerosis (ISA) in Boston, MA.
    • 30 Aug 2008 24-week interim results presented at the 2008 Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top